Endocrine

, Volume 48, Issue 1, pp 65–68 | Cite as

Osteoporosis in patients taking selective serotonin reuptake inhibitors: a focus on fracture outcome

Mini Review

Abstract

Depression is one of the most important mental health problems and a leading cause of disability. Selective serotonin reuptake inhibitors (SSRIs) are considered as first-line therapy for the treatment of depressive symptoms among older adults because of their presumed favorable adverse effect profile. However, they could have deleterious effects on the bone. Evidence from longitudinal, cross-sectional, and prospective cohort studies suggests that the use of antidepressants at therapeutic doses is associated with decreased bone mineral density and increased fracture risk. The association between SSRIs use and fracture risk could potentially differ depending on dose, exposure duration, time of exposure, age, or sex. However, the risk of fracture declined rapidly after discontinuation of use of SSRIs. The evidence now seems sufficient to consider adding SSRIs to the list of medications that contribute to osteoporosis. In practice, assessment of risk factor for osteoporosis or fractures could be made taking into account age, gender, duration, and severity of depression, length of SSRI treatments, and other concurrent risk factors.

Keywords

Depression Osteoporosis Fracture Antidepressants Selective serotonin reuptake inhibitors 

References

  1. 1.
    E.S. Paykel, Depression: major problem for public health. Epidemiol. Psichiatr. Soc. 15(1), 4–10 (2006)PubMedGoogle Scholar
  2. 2.
    R.S. Shim, P. Baltrus, J. Ye, G. Rust, Prevalence, treatment, and control of depressive symptoms in the United States: results from the National Health and Nutrition Examination Survey (NHANES), 2005–2008. J. Am. Board Fam. Med. 24(1), 33–38 (2011). doi:10.3122/jabfm.2011.01.100121 CrossRefPubMedCentralPubMedGoogle Scholar
  3. 3.
    J. Alonso, M.C. Angermeyer, S. Bernert, R. Bruffaerts, T.S. Brugha, H. Bryson, G. de Girolamo, R. Graaf, K. Demyttenaere, I. Gasquet, J.M. Haro, S.J. Katz, R.C. Kessler, V. Kovess, J.P. Lepine, J. Ormel, G. Polidori, L.J. Russo, G. Vilagut, J. Almansa, S. Arbabzadeh-Bouchez, J. Autonell, M. Bernal, M.A. Buist-Bouwman, M. Codony, A. Domingo-Salvany, M. Ferrer, S.S. Joo, M. Martinez-Alonso, H. Matschinger, F. Mazzi, Z. Morgan, P. Morosini, C. Palacin, B. Romera, N. Taub, W.A. Vollebergh, Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr. Scand. 190(s420), 21–27 (2004). doi:10.1111/j.1600-0047.2004.00327.x Google Scholar
  4. 4.
    M. Moore, H.M. Yuen, N. Dunn, M.A. Mullee, J. Maskell, T. Kendrick, Explaining the rise in antidepressant prescribing: a descriptive study using the general practice research database. BMJ 339, b3999 (2009). doi:10.1136/bmj.b3999 CrossRefPubMedCentralPubMedGoogle Scholar
  5. 5.
    P. Lockhart, B. Guthrie, Trends in primary care antidepressant prescribing 1995–2007: a longitudinal population database analysis. Br. J. Gen. Pract. 61(590), e565–e572 (2011). doi:10.3399/bjgp11X593848 CrossRefPubMedCentralPubMedGoogle Scholar
  6. 6.
    R. Rizzoli, C. Cooper, J.Y. Reginster, B. Abrahamsen, J.D. Adachi, M.L. Brandi, O. Bruyere, J. Compston, P. Ducy, S. Ferrari, N.C. Harvey, J.A. Kanis, G. Karsenty, A. Laslop, V. Rabenda, P. Vestergaard, Antidepressant medications and osteoporosis. Bone 51(3), 606–613 (2012). doi:10.1016/j.bone.2012.05.018 CrossRefPubMedGoogle Scholar
  7. 7.
    O. Spigset, B. Martensson, Fortnightly review: drug treatment of depression. BMJ 318(7192), 1188–1191 (1999)CrossRefPubMedCentralPubMedGoogle Scholar
  8. 8.
    E.M. Haney, S.J. Warden, M.M. Bliziotes, Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management? Bone 46(1), 13–17 (2010). doi:10.1016/j.bone.2009.07.083 CrossRefPubMedCentralPubMedGoogle Scholar
  9. 9.
    P. Ducy, G. Karsenty, The two faces of serotonin in bone biology. J. Cell Biol. 191(1), 7–13 (2010). doi:10.1083/jcb.201006123 CrossRefPubMedCentralPubMedGoogle Scholar
  10. 10.
    E.M. Haney, S.J. Warden, Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from clinical studies. J. Musculoskelet. Neuronal Interact. 8(2), 133–145 (2008)PubMedGoogle Scholar
  11. 11.
    S.J. Diem, T.L. Blackwell, K.L. Stone, K. Yaffe, E.M. Haney, M.M. Bliziotes, K.E. Ensrud, Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch. Intern. Med. 167(12), 1240–1245 (2007). doi:10.1001/archinte.167.12.1240 CrossRefPubMedGoogle Scholar
  12. 12.
    L.J. Williams, M.J. Henry, M. Berk, S. Dodd, F.N. Jacka, M.A. Kotowicz, G.C. Nicholson, J.A. Pasco, Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression. Int. Clin. Psychopharmacol. 23(2), 84–87 (2008). doi:10.1097/YIC.0b013e3282f2b3bb CrossRefPubMedGoogle Scholar
  13. 13.
    E.M. Haney, B.K. Chan, S.J. Diem, K.E. Ensrud, J.A. Cauley, E. Barrett-Connor, E. Orwoll, M.M. Bliziotes, Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch. Intern. Med. 167(12), 1246–1251 (2007). doi:10.1001/archinte.167.12.1246 CrossRefPubMedGoogle Scholar
  14. 14.
    R. Ginzburg, E. Rosero, Risk of fractures with selective serotonin-reuptake inhibitors or tricyclic antidepressants. Ann. Pharmacother. 43(1), 98–103 (2009). doi:10.1345/aph.1L264 CrossRefPubMedGoogle Scholar
  15. 15.
    S. Schwan, P. Hallberg, SSRIs, bone mineral density, and risk of fractures—a review. Eur. Neuropsychopharmacol. 19(10), 683–692 (2009). doi:10.1016/j.euroneuro.2009.05.001 CrossRefPubMedGoogle Scholar
  16. 16.
    V. Rabenda, O. Bruyere, J.Y. Reginster, Risk of nonvertebral fractures among elderly postmenopausal women using antidepressants. Bone 51(4), 674–679 (2012). doi:10.1016/j.bone.2012.07.030 CrossRefPubMedGoogle Scholar
  17. 17.
    M.S. Bakken, A. Engeland, L.B. Engesaeter, A.H. Ranhoff, S. Hunskaar, S. Ruths, Increased risk of hip fracture among older people using antidepressant drugs: data from the Norwegian Prescription Database and the Norwegian Hip Fracture Registry. Age Ageing 42(4), 514–520 (2013). doi:10.1093/ageing/aft009 CrossRefPubMedGoogle Scholar
  18. 18.
    D. Prieto-Alhambra, H. Petri, J.S. Goldenberg, T.P. Khong, O.H. Klungel, N.J. Robinson, F. de Vries, Excess risk of hip fractures attributable to the use of antidepressants in five European countries and the USA. Osteoporos. Int. 25(3), 847–855 (2014). doi:10.1007/s00198-013-2612-2 CrossRefPubMedGoogle Scholar
  19. 19.
    C. Moura, S. Bernatsky, M. Abrahamowicz, A. Papaioannou, L. Bessette, J. Adachi, D. Goltzman, J. Prior, N. Kreiger, T. Towheed, W.D. Leslie, S. Kaiser, G. Ioannidis, L. Pickard, L.A. Fraser, E. Rahme, Antidepressant use and 10-year incident fracture risk: the population-based Canadian Multicentre Osteoporosis Study (CaMoS). Osteoporos. Int. 25(5), 1473–1481 (2014). doi:10.1007/s00198-014-2649-x CrossRefPubMedGoogle Scholar
  20. 20.
    J.J. Gagne, A.R. Patrick, H. Mogun, D.H. Solomon, Antidepressants and fracture risk in older adults: a comparative safety analysis. Clin. Pharmacol. Ther. 89(6), 880–887 (2011). doi:10.1038/clpt.2011.54 CrossRefPubMedGoogle Scholar
  21. 21.
    G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatments for osteoporosis. Endocrine 41(1), 58–69 (2012). doi:10.1007/s12020-011-9570-2 CrossRefPubMedGoogle Scholar
  22. 22.
    J.F. Griffith, H.K. Genant, New advances in imaging osteoporosis and its complications. Endocrine 42(1), 39–51 (2012). doi:10.1007/s12020-012-9691-2 CrossRefPubMedGoogle Scholar
  23. 23.
    Q. Wu, W. Qu, M.D. Crowell, J.G. Hentz, K.A. Frey, Tricyclic antidepressant use and risk of fractures: a meta-analysis of cohort and case-control studies. J. Bone Miner. Res. 28(4), 753–763 (2013). doi:10.1002/jbmr.1813 CrossRefPubMedGoogle Scholar
  24. 24.
    V. Rabenda, D. Nicolet, C. Beaudart, O. Bruyere, J.Y. Reginster, Relationship between use of antidepressants and risk of fractures: a meta-analysis. Osteoporos. Int. 24(1), 121–137 (2013). doi:10.1007/s00198-012-2015-9 CrossRefPubMedGoogle Scholar
  25. 25.
    C.S. Eom, H.K. Lee, S. Ye, S.M. Park, K.H. Cho, Use of selective serotonin reuptake inhibitors and risk of fracture: a systematic review and meta-analysis. J. Bone Miner. Res 27(5), 1186–1195 (2012). doi:10.1002/jbmr.1554 CrossRefPubMedGoogle Scholar
  26. 26.
    L.H. Oderda, J.R. Young, C.V. Asche, G.A. Pepper, Psychotropic-related hip fractures: meta-analysis of first-generation and second-generation antidepressant and antipsychotic drugs. Ann. Pharmacother. 46(7–8), 917–928 (2012). doi:10.1345/aph.1Q589 CrossRefPubMedGoogle Scholar
  27. 27.
    J.Y. Reginster, R. Deroisy, I. Paul, M. Hansenne, M. Ansseau, Depressive vulnerability is not an independent risk factor for osteoporosis in postmenopausal women. Maturitas 33(2), 133–137 (1999)CrossRefPubMedGoogle Scholar
  28. 28.
    C.V. Phillips, K.J. Goodman, The missed lessons of Sir Austin Bradford Hill. Epidemiol. Perspect. Innov. 1(1), 3 (2004). doi:10.1186/1742-5573-1-3 CrossRefPubMedCentralPubMedGoogle Scholar
  29. 29.
    M.W. van den Brand, S. Pouwels, M.M. Samson, T.P. van Staa, B. Thio, C. Cooper, H.G. Leufkens, A.C. Egberts, H.J. Verhaar, F. de Vries, Use of anti-depressants and the risk of fracture of the hip or femur. Osteopor. Int. 20(10), 1705–1713 (2009). doi:10.1007/s00198-009-0849-6 CrossRefGoogle Scholar
  30. 30.
    P. Vestergaard, D. Prieto-Alhambra, M.K. Javaid, C. Cooper, Fractures in users of antidepressants and anxiolytics and sedatives: effects of age and dose. Osteoporos. Int. 24(2), 671–680 (2013). doi:10.1007/s00198-012-2043-5 CrossRefPubMedCentralPubMedGoogle Scholar
  31. 31.
    J.M. Robine, E. Cambois, W. Nusselder, B. Jeune, H.V. Oyen, C. Jagger, The joint action on healthy life years (JA: EHLEIS). Arch. Public Health 71(1), 2 (2013). doi:10.1186/0778-7367-71-2 CrossRefPubMedCentralPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Public Health, Epidemiology and Health EconomicsUniversity of LiègeLiègeBelgium

Personalised recommendations